News | September 27, 2024
Zydus and CSIR-CDRI Lucknow to develop drug for CKD induced Osteoporosis
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Stable profits, low leverage to keep credit profiles comfortable
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
ALS patients experience neuroinflammation and rapid neurodegeneration
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Subscribe To Our Newsletter & Stay Updated
